期刊文献+

类固醇对免疫检查点抑制剂治疗非小细胞肺癌疗效影响的meta分析 被引量:1

Effect of steroids on the immune checkpoint inhibitors for non-small cell lung cancer:a meta-analysis
下载PDF
导出
摘要 目的系统评价类固醇的使用对接受免疫检查点抑制剂(ICIs)治疗非小细胞肺癌(NSCLC)患者无进展生存期(PFS)和总生存期(OS)的影响。方法计算机检索PubMed、EMbase、Cochrane Library、Web of Science以及中国知网、维普、万方等数据库,收集接受ICIs治疗的NSCLC患者使用与未使用类固醇对PFS和OS影响的前瞻性或回顾性研究,检索时间为自建库至2021年4月。由两名研究者独立评价纳入研究的质量、提取资料并交叉核对,采用RevMan 5.3软件进行meta分析;采用Stata 15.0软件进行发表偏倚分析。结果共纳入16项回顾性队列研究,共6682例患者。Meta分析结果显示:与未使用类固醇的患者相比,类固醇的使用降低了患者的PFS[HR=1.50,95%CI(1.25,1.80),P<0.0001]和OS[HR=1.56,95%CI(1.31,1.86),P<0.00001]。亚组分析结果显示:ICIs治疗开始后使用类固醇降低了患者的PFS[HR=1.99,95%CI(1.52,2.60),P<0.00001]和OS[HR=2.33,95%CI(1.61,3.36),P<0.00001];ICIs治疗开始前使用类固醇与患者的PFS和OS无相关性(P>0.05)。因癌症相关症状接受类固醇治疗降低了患者的PFS[HR=1.57,95%CI(1.32,1.88),P<0.00001]和OS[HR=1.65,95%CI(1.21,2.24),P=0.001]。结论在接受ICIs治疗的NSCLC患者中,类固醇的使用与患者较差的预后相关,特别是在ICIs治疗开始后使用或者因癌症相关症状使用,而在ICIs治疗开始前使用类固醇可能不会影响患者的预后。 Objective To systematically evaluate the effect of steroids use on progression-free survival(PFS)and overall survival(OS)of patients treated with immune checkpoint inhibitors(ICIs)for non-small cell lung cancer(NSCLC).Methods Computerized retrieval of PubMed,EMbase,Cochrane Library,Web of Science,CNKI,VIP,Wanfang and other databases was conducted to collect prospective or retrospective studies on the effect of steroids use and non-use on PFS and OS in NSCLC patients treated with ICIs.The retrieval covered from the self-built database to April 2021.Two researchers independently evaluated the quality of the included studies,collected data and cross-checked them.Meta-analysis was performed with RevMan 5.3 software.Stata 15.0 software was used to analyze publication bias.Results Totally 16 retrospective cohort studies involving 6682 patients were included.Meta-analysis showed that the use of steroids reduced PFS[HR=1.50,95%CI(1.25,1.80),P<0.0001]and OS[HR=1.56,95%CI(1.31,1.86),P<0.00001]in patients compared with those who did not use steroids.Subgroup analysis showed that steroids use after the onset of ICIs reduced PFS[HR=1.99,95%CI(1.52,2.60),P<0.00001]and OS[HR=2.33,95%CI(1.61,3.36),P<0.00001].Steroids use before ICIs had no significant correlation with PFS and OS.(P>0.05).Steroids use for cancer-related symptoms reduced PFS[HR=1.57,95%CI(1.32,1.88),P<0.00001]and OS[HR=1.65,95%CI(1.21,2.24),P=0.001].Conclusion Steroids use is associated with poorer prognosis in NSCLC patients treated with ICIs,especially after the onset of ICIs or due to cancer-related symptoms,whereas steroids use before the onset of ICIs is not likely to affect patient outcomes.
作者 王瑞航 华鹏 刘晓波 廖思 江晓春 WANG Rui-hang;HUA Peng;LIU Xiao-bo;LIAO Si;JIANG Xiao-chun(College of Pharmacy,Dali University,Dali Yunnan 671000;Department of Pharmacy,Yunnan Third People’s Hospital,Kunming 650000;Department of Blood Transfusion,Yunnan Third People’s Hospital,Kunming 650000)
出处 《中南药学》 CAS 2022年第3期678-685,共8页 Central South Pharmacy
基金 云南省科学技术厅--云南中医学院应用基础研究联合专项项目[No.2018FF001(-062)]。
关键词 类固醇 免疫检查点抑制剂 非小细胞肺癌 META分析 steroids immune checkpoint inhibitor non-small cell lung cancer meta analysis
  • 相关文献

参考文献2

  • 1H.Agakishiev,M.M.Aggarwal,Z.Ahammed,A.V.Alakhverdyants,I.Alekseev,J.Alford,B.D.Anderson,C.D.Anson,D.Arkhipkin,G.S.Averichev,J.Balewski,D.R.Beavis,N.K.Behera,R.Bellwied,M.J.Betancourt,R.R.Betts,A.Bhasin,A.K.Bhat,H.Bichsel,J.Bieleik,J.Bielcikova,B.Biritz,L.C.Bland,W.Borowski,J.Bouchet,E.Braidot,A.V.Brandin,A.Bridgeman,S.G.Brovko,E.Bruna,S.Bueltmann,I.Bunzarov,T.P.Burton,X.Z.Cai,H.Caines,M.Calderon de la Barca Sanchez,D.Cebra,R.Cendejas,M.C.Cervantes,Z.Chajecki,P.Chaloupka,S.Chattopadhyay,H.F.Chen,J.H.Chen,J.Y.Chen,L.Chen,J.Cheng,M.Cherney,A.Chikanian,K.E.Choi,W.Christie,P.Chung,M.J.M.Codrington,R.Corliss,J.G.Cramer,H.J.Crawford,S.Dash,A.Davila Leyva,L.C.De Silvat,R.R.Debbe,T.G.Dedovich,A.A.Derevschikov,R.Derradi de Souza,L.Didenko,P.Djawotho,S.M.Dogra,X.Dong,J.L.Drachenberg,J.E.Draper,J.C.Dunlop,L.G Efimov,M.Elnim,J.Engelage,G Eppley,M.Estienne,L.Eun,O.Evdokimov,R.Fatemi,J.Fedorisin,A.Feng,R.G.Fersch,P.Filip,E.Finch,V.Fine,Y.Fisyak,C.A.Gagliardi,D.R.Gangadharan,A.Geromitsos,F.Geurts,P.Ghosh,Y.N.Gorbunov,A.Gordon,O.Grebenyuk,D.Grosnick,S.M.Guertin,A.Gupta,W.Guryn,B.Haag,O.Hajkova,A.Hamed,L-X.Han,J.W.Harris,J.P.Hays-Wehle,M.Heinz,S.Heppelmann,A.Hirsch,E.Hjort,G.W.Hoffmann,D.J.Hofiman,B.Huang,H.Z.Huang,T.J.Humanic,L.Huo,G.Igo,P.Jacobs,W.W.Jacobs,C.Jena,F.Jin,J.Joseph,E.G.Judd,S.Kabana,K.Kang,J.Kapitan,K.Kauder,H.Ke,D.Keane,A.Kechechyan,D.Kettler,D.P.Kikola,J.Kiryluk,A.Kisiel,V.Kizka,A.G.Knospe,D.D.Koetke,T.Kollegger,J.Konzer,I.Koralt,L.Koroleva,W.Korsch,L.Kotchenda,V.Kouchpil,P.Kravtsov,K.Krueger.Measurements of dihadron correlations relative to the event plane in Au+Au collisions at√^(S)NN=200 GeV[J].Chinese Physics C,2021,45(4):198-241. 被引量:351
  • 2Ying Cheng,Hui Li,Liang Zhang,Jing-Jing Liu,Chang-Liang Yang,Shuang Zhang.Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer[J].Chinese Medical Journal,2021(15):1780-1788. 被引量:8

二级参考文献3

共引文献357

同被引文献25

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部